Sapporo Clinical Laboratory Inc.

9776

JP3321100004

Drug Retailers

Delayed Japan Exchange Other stock markets 09:50:07 2024-04-29 pm EDT			5-day change	1st Jan Change
1,076 ^JPY	-0.37%		-0.74%	+7.49%

Mar. 27	Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 26, 2024.	CI
Mar. 26	Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on March 26, 2024, has closed with 210,800 shares, representing 6.33% for ¥189.93 million.	CI

Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 28, 2022.

March 28, 2022 at 08:00 pm EST

From February 28, 2022 to March 1, 2022, the company has repurchased 53,700 shares, representing 1.58% for ¥69.11 million. With this, the company has completed the repurchase of 53,700 shares, representing 1.58% for ¥69.11 million under the buyback announced on February 28, 2022.

Latest news about Sapporo Clinical Laboratory Inc.

Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 26, 2024.	Mar. 27	CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on March 26, 2024, has closed with 210,800 shares, representing 6.33% for ¥189.93 million.	Mar. 25	CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 232,100 shares, representing 6.97% for ¥209.12 million.	Feb. 26	CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan.	Feb. 25	CI
Sapporo Clinical Laboratory Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on May 30, 2022.	22-05-30	CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on May 30, 2022 has closed with 22,700 shares, representing 0.67% for ¥29.21 million.	22-05-30	CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 22,700 shares, representing 0.68% for ¥29.21 million.	22-05-30	CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan.	22-05-29	CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 28, 2022.	22-02-28	CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on February 28, 2022, has closed with 53,700 shares, representing 1.58% for ¥69.11 million.	22-02-28	CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 53,700 shares, representing 1.58% for ¥69.11 million.	22-02-28	CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan.	22-02-27	CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on June 21, 2021.	21-06-21	CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on June 21, 2021, has closed with 16,300 shares, representing 0.48% for ¥25.92 million.	21-06-21	CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 16,300 shares, representing 0.48% for ¥25.92 million.	21-06-21	CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan.	21-06-20	CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on June 26, 2018.	18-06-26	CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on June 26, 2018 has expired with 39,200 shares, representing 1.13% for ¥96 million.	18-06-26	CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 45,000 shares, representing 1.3% for ¥110.21 million.	18-06-26	CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan.	18-06-25	CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 26, 2018.	18-02-26	CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on February 26, 2018 has expired with 16,800 shares for ¥32.26 million.	18-02-26	CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 20,000 shares, representing 0.57% for ¥38.4 million.	18-02-26	CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan.	18-02-25	CI

Chart Sapporo Clinical Laboratory Inc.

Duration

Period

More charts

Company Profile

SAPPORO CLINICAL LABORATORY INC. is a Japan-based company mainly engaged in the dispensing pharmacy business. The Company operates in three business segments. The Clinical Examination segment is engaged in the provision of clinical examination needed in medical examinations in hospitals. The Dispensing Pharmacy segment is engaged in operation of dispensing pharmacies, as well as wholesale of drugs and medicines. The Medical Equipment Sale and Maintenance segment is engaged in the sale and maintenance of high level medical equipment, general medical equipment, as well as physics and chemistry equipment. The others business is engaged in the development, sale and maintenance of software for clinical examination system.

Sector

Drug Retailers

Calendar

2024-05-12 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
SAPPORO CLINICAL LABORATORY INC.	+7.49%	22.85M
RAIA DROGASIL S.A.	-12.48%	8.57B
AIN HOLDINGS INC.	+34.96%	1.32B
QOL HOLDINGS CO., LTD.	+6.58%	419M
NIHON CHOUZAI CO.,LTD.	+8.22%	282M
SALUS, LJUBLJANA, D. D.	+10.56%	224M
GREEN CROSS HEALTH LIMITED	-8.26%	85.07M
MEDICAL IKKOU GROUP CO.,LTD.	+21.18%	59.57M

Retail - Drugs without Grocery

Sapporo Clinical Laboratory Inc.

Equities

9776

JP3321100004

Drug Retailers

Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 28, 2022.

Latest news about Sapporo Clinical Laboratory Inc.

Chart Sapporo Clinical Laboratory Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Retail - Drugs without Grocery